Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Investor Presentation (May 2026)
28 slides from Pelthos Therapeutics's investor presentation, May 14, 2026
Slide 1: Corporate Presentation May 2026
1 Corporate Presentation M A Y 2 0 2 6 Exhibit 99.2
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “anticipate,” “believe,” “continue,” “could,” “esti
Slide 3: Investment Highlight and Product Portfolio
33 • Large addressable market with $2,008.50 wholesale acquisition cost (”WAC”) • Launched July 2025 • Modest acquisition cost, unencumbered future revenue stream • Expected launch early 2027 • 6–12 million U.S. cases annually • Expected launch mid-2027 Investment Highlight Commercial biopharmaceu
Slide 4: Corporate Profile
4 Corporate Profile Key Data Points (as of 05/11/26, except where noted) PTHSTicker $26.85Stock Price ~8.9MO/S Shares of Common Stock (with Pref A conversion) ~$240MMarket Cap ~12,000 shares (Yahoo) 60-Day Avg. Daily Trading Volume $32.0MCash at end of Q1 2026 Pelthos is a competitive drug portfolio
Slide 5: Management Team
5 Management Team John M. Gay | Chief Financial Officer Sai Rangarao | Chief Commercial Officer Scott Plesha | Chief Executive Officer • >30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial efforts • President and Chief Commer
Slide 6: Molluscum & Zelsuvmi Overview
Molluscum & Zelsuvmi Overview
Slide 7: Molluscum Contagiosum
7 Molluscum Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older There are four known types of MC virus (MCV1, 2, 3, 4) with MCV1 being the most common1 Molluscum Contagiosum is caused by a pox virus and is characterized by small, round, firm, umbilicat
Slide 8: Zelsuvmi Has the Potential to Shift MC Treatment Paradigm
8 Zelsuvmi Has the Potential to Shift MC Treatment Paradigm Previous Treatment Options • Painful, destructive treatments3 • Attractive safety profile demonstrated in clinical trials with no / minimal scarring5,6 • Remaining treatment options such as off-label drugs / natural remedies have unproven e
Slide 9: Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch
9 InterventionPopulation Key Study Highlights B-SIMPLE4 Primary OutcomeB-SIMPLE4 Study Locations 1) p-value <0.0001, favoring Zelsuvmi .. Source: Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum conta
Slide 10: Phase 3 Trial Results
10CONFIDENTIAL Baseline Week 2 Week 4 0.0% -1.1 % -43.5% Week 8 -35.7% Week 12 -59.4% -82.4% -42.6% -10.7% - 25 .1% -9.0% -21 .6% - 58 .1% Baseline Week 2 Week 4 0.0% 0.0% -9.5% -10.0% -28.6% -27.8% Week 8 Week 12 Phase 3 Trial Results 1) Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda
Slide 11: Zelsuvmi Commercial Overview
Zelsuvmi Commercial Overview
Slide 12: Strong Zelsuvmi Quarter over Quarter Growth Continues
1212 Data Source: Symphony Health- Metys Data Strong Zelsuvmi Quarter over Quarter Growth Continues Total of 4,867 Unique PrescribersTotal of 16,774 Prescribed Units 2,578 6,312 7,884 0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 2025-Q3 2025-Q4 2026-Q1 Zelsuvmi TRx Units 1,223 2,377 3,228
Slide 13: Zelsuvmi Covered Lives by Quarter
1313 Zelsuvmi Covered Lives by Quarter* • Selective contracting strategy • 70% combined Medicaid/commercial coverage with 1 contract • Favorable Gross to Nets • Favorable approval rates with all payers *Clarivate (DRG) Fingertip Formulary • Commercial, Cash and Assistance Programs - 71% of TRxs • Ma
Slide 14: Strong Sales Team Execution
1414 Strong Sales Team Execution Fully built out commercial team: • 64 Sales Territories expansion completed & onboarded covering ~53% of MC Claims • Territories expansion complete, contributing to • Zelsuvmi growth • Sales Team targeting: Pediatric/Adult Dermatologists, General Pediatrics, Nurse Pr
Slide 15: Robust Zelsuvmi Tactical Execution
15 Robust Zelsuvmi Tactical Execution Digital Marketing National & Regional Conference Presence YouTube Promotional Commercial Live & Virtual Educational Speaker Development New Patient Testimonials & Information ZELSUVMI GO Patient Support Program
Slide 16: Xepi: New Product Acquisition
Xepi: New Product Acquisition
Slide 17: Xepi (ozenoxacin) Cream for the treatment of Impetigo
17 Xepi (ozenoxacin) Cream for the treatment of Impetigo Sources: CDC Website, Xepi Pack Insert, FDA.gov • Ozenoxacin cream 1% developed as first line treatment in patients aged 2 months and older • 15 clinical studies in Phase 1 & 2 conducted • Two Pivotal Phase 3 studies conducted in both adult &
Slide 18: Xeglyze: New Product Acquisition
Xeglyze: New Product Acquisition
Slide 19: Xeglyze (abametapir) Lotion for the Treatment of Head Lice
19 Xeglyze (abametapir) Lotion for the Treatment of Head Lice Sources: CDC Website, Xepi Pack Insert, FDA.gov • Abametapir lotion 0.74% developed as first line treatment in patients aged 6 months of age and older • Phase 2b study completed in 2014 demonstrated 100% ovicidal efficacy • Two Pivotal Ph
Slide 20: Summary Financial Statements
Summary Financial Statements
Slide 21: Summary Balance Sheet
2121 Summary Balance Sheet • Cash balance includes $30 million raised with Horizon Loan Facility in January 2026 with issuance of 5-year term notes; additional tranches totaling $20 million available on hitting certain milestones • Working capital of $44.8 million as of March 31, 2026 • Strong stock
Slide 22: Summary Income Statement
2222 Summary Income Statement • Net product revenue increased 17% quarter over quarter • SG&A expenses increased 14% quarter over quarter, related primarily to personnel costs, marketing, and manufacturing expenses • SG&A includes royalties and non-cash expenses (stock- based compensation and deprec
Slide 23: Appendix
Appendix MA Pelthos Therapeutics
Slide 24: Nitricil Platform Pipeline
24 Nitricil Platform Pipeline* Approximate Time to NDA Filing Asset DescriptionIndication 7.5 years Berdazimer topical cream, dose TBD, for treatment of mild to moderate atopic dermatitis. Phase 1/2 Clinical stage. SB414 (AD/Psoriasis) 5 years (T. Pedis) 6.5 years (Onychomycosis) Low alcohol berdazi
Slide 25: NaV1.7 Pipeline
25 NaV1.7 Pipeline Approximate Time to NDA Filing Asset DescriptionIndication 3-4 yearsCC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready CT2000 Eye Drops Chronic Ocular Pain 2-3 yearsCC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready CT2000 Eye Drops Acute Ocular Pain 5+ yea
Slide 26: Board of Directors
26 Board of Directors Peter Greenleaf, Chairman Richard Baxter Ezra Friedberg Todd Davis Richard Malamut , MD Matt Pauls Scott Plesha Andrew Einhorn
Slide 27: Operating Leverage and Key Investment Points
27 Operating Leverage All three products utilize the same sales team, with largely overlapping call points, provides greater operating and financial leverage with very little dedicated overhead Portfolio of FDA Approved Products Differentiated portfolio of novel, cutaneous infectious disease product
Slide 28: Thank You
28 Thank You C o n t a c t s I n v e s t o r I n q u i r i e s : M i k e M o y e r L i f e S c i A d v i s o r s , L L C M a n a g i n g D i r e c t o r m m o y e r @ l i f e s c i a d v i s o r s . c o m M e d i a : K W M C o m m u n i c a t i o n s K e l l i e W a l s h / R a c h e l K e s s l e r
Pelthos Therapeutics — Investor Presentation (May 2026) on 6ix